China's clinical trial capacity matches US, attracts more global pharma firms, investors

Core Insights - China's expanding pipeline of novel drug candidates is attracting global pharmaceutical companies and investors seeking licensing opportunities due to the country's clinical trial capacity now matching that of the US [1][3] Group 1: Clinical Trials in China - There is a growing interest from multinational corporations in conducting investigator-initiated trials for cell and gene therapies in China, as they can access patient data more quickly than in other markets [2] - As of 2024, China's clinical trial volumes have reached 80% of those in the US and are 10% higher than in Europe, indicating significant growth in the sector [3] - In 2024, China recorded 2,694 new clinical trials, a 13% increase from the previous year, with multinational companies accounting for 14.3% of these trials, reflecting a 7% compound annual growth rate since 2019 [4] Group 2: Market Dynamics and Future Outlook - Despite geopolitical tensions, multinational firms are not expected to slow down their clinical trials in China, as it remains the second-largest pharmaceutical market globally [5] - Chinese policymakers are anticipated to provide more targeted support for research and development and commercialization in the biomedical manufacturing sector, which could further enhance the growth of innovative clinical trials [5]